Nanexa AB - Home

Capital markets day at the Royal Swedish Academy of Engineering Sciences IVA in Stockholm

David welcomes

Mårten presents

Kristine presents

PRESSRELEASES

28 June, 2024

Nanexa appoints new Chief Financial Officer

Nanexa AB (publ) today announces that Cecilia Danckwardt-Lillieström will take over as Chief Financial Officer as of September 1, 2024, as the current CFO Björn Svanström has chosen to leave the company.

11 June, 2024

First patient dosed in Nanexa’s Phase I trial of NEX-22 in type 2 diabetes

Nanexa AB today announces that the company’s Phase 1 study for type 2 diabetes has been initiated with dosing of the first patient. The study evaluates a long-acting depot formulation of the GLP-1 analog liraglutide with Nanexa’s patented PharmaShell® system within the NEX-22 project. The study is a dose-escalation study aimed at evaluating the pharmacokinetic profile, safety and tolerability of different doses.